AI Model Slashes IBD Trial Times, Offers Hope for Faster Cures

STOCKHOLM, SWEDEN – February 19, 2026 – New research presented this week at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO) has unveiled a breakthrough in clinical trial efficiency, demonstrating a model that can enroll patients with inflammatory bowel disease (IBD) more than three times faster than industry averages. The data, from healthcare technology firm Iterative Health, validates a site-centric network that leverages artificial intelligence and standardized operations to dramatically cut trial timelines, offering a potential solution to a long-standing crisis in drug development.

The study, titled “Accelerating enrollment in phase 2 and 3 inflammatory bowel disease trials through an innovative site network,” detailed unprecedented performance metrics. Across multiple Phase 2 and 3 trials for ulcerative colitis and Crohn’s disease, sites within Iterative Health’s network enrolled patients at an average rate of 0.34 per month. This figure is approximately 3.4 times higher than published industry benchmarks, which hover around 0.10 patients per site per month. Furthermore, the model slashed the time needed to get trial sites running, reducing the median activation timeline from selection to activation to just 74 days—a significant improvement over the industry standard of 120 to 171 days, representing a potential time savings of nearly three months per site.

Confronting a Crisis in IBD Research

These results arrive at a critical moment for IBD research. For over a decade, the field has been grappling with a severe and worsening “recruitment crisis.” According to published data, per-site randomization rates for ulcerative colitis and Crohn’s disease trials have plummeted by more than 70% since the late 1990s. This decline creates a major bottleneck, delaying the development of new treatments and prolonging the suffering of patients who have exhausted existing options.

The challenges are multifaceted. Patients often face restrictive eligibility criteria that exclude them from participating, while physicians and research sites are burdened by increasingly complex protocols, administrative overhead, and a lack of dedicated resources for patient identification. Industry reports from organizations like the Tufts Center for the Study of Drug Development have long highlighted that a significant portion of clinical trial sites fail to meet their enrollment targets, with some failing to enroll a single patient. This inefficiency not only inflates costs but, more importantly, creates a “therapy gap” where promising drugs are stuck in development pipelines for years.

“The research investigated an innovative approach to longstanding challenges in clinical research related to trial delays and lagging enrollment rates across sites,” said Laurent Peyrin-Biroulet, MD, PhD, a professor of gastroenterology and the study's lead author. “With per-site randomization rates falling by more than 70% over the last decade in ulcerative colitis and Crohn’s disease, the consistency and scale of performance observed by the Iterative Health site network points to a more sustainable way to drive the development of novel therapies for patients.”

The Anatomy of a Breakthrough

At the heart of Iterative Health's success is its “site-centric partnership model,” an integrated system designed to embed research directly into community-based care settings. Rather than simply contracting with disparate sites, the company builds a global network empowered with a suite of tools and support systems. This approach fundamentally re-engineers the trial process from the ground up.

The model rests on three key pillars. First, it provides a robust operational infrastructure that standardizes and streamlines complex processes like site start-up, regulatory submissions, and budget negotiations. This high-touch support reduces the administrative burden that often overwhelms site staff. Second, sites receive study-specific training and continuous education, ensuring research teams are well-equipped to manage complex protocols and workflows.

The third, and perhaps most transformative, element is the use of AI-powered technology. These proprietary tools are designed to integrate into a gastroenterologist's daily workflow, helping to identify eligible patients for trials more effectively and standardize the assessment of disease activity, a notoriously subjective process in IBD. By applying AI to endoscopic video and other clinical data, the system can speed up eligibility assessments and improve the quality and consistency of data collection, addressing two major pain points in IBD trials.

“When a purpose-built clinical research infrastructure focuses on high-performing, sustainable, community-based research sites, it becomes possible to set a higher standard for enrollment and speed,” noted J. Casey Chapman, MD, study author and Chief Medical Officer of GI Alliance. “Trials can move forward more efficiently, expanding access to treatment options and ultimately advancing patient care.”

A New Blueprint for Clinical Research

The consistency of these results—observed across U.S. and European sites, Phase II and III trials, and both ulcerative colitis and Crohn's disease—suggests the model is not a fluke but a scalable and replicable blueprint. By proving its effectiveness in the notoriously difficult IBD space, Iterative Health is making a strong case for its applicability in other complex therapeutic areas.

The performance data represents a significant challenge to the status quo in the clinical research industry, where large contract research organizations (CROs) and technology providers have long sought solutions to the efficiency problem. The validation of this site-centric, AI-enhanced model could catalyze a shift in the market toward more integrated and specialized partnerships that prioritize empowering the investigative sites where the research actually happens.

Company leadership has confirmed this is just the beginning. The data presented at ECCO is the first aggregated performance report from the company, signaling a commitment to data-driven validation of its methods.

“This publication marks the first time Iterative Health has reported aggregated performance metrics and reflects our promise of data-driven and impactful innovation,” said Dana Feuchtbaum, Chief Operating Officer of Iterative Health. “The results demonstrate a business model that is intentionally designed to accelerate clinical research, paving the way to expand across GI, hepatology, and additional therapeutic areas.”

By directly tackling the root causes of trial delays, this innovative approach promises more than just better business metrics for pharmaceutical sponsors. For millions of patients living with chronic diseases, it represents a tangible hope for faster access to the next generation of life-changing medicines. The success in IBD may soon serve as the foundation for accelerating medical progress across a much wider spectrum of human disease.